STOCK TITAN

Atea Pharmaceuticals (AVIR) SEC Filings, May-Jun 2026

AVIR NASDAQ

Atea Pharmaceuticals SEC filings document the regulatory record of a Nasdaq-listed clinical biopharmaceutical company developing oral antiviral therapies. Form 8-K reports furnish financial results, preliminary financial information, business updates, and exhibit press releases that describe the company’s HCV and HEV antiviral programs.

Proxy and annual meeting filings cover governance matters, director elections, auditor ratification, executive compensation, pay-versus-performance disclosures, and stockholder voting results. The filings also identify Atea’s common stock, par value $0.001 per share, traded under AVIR on The Nasdaq Global Select Market.

Rhea-AI Summary

Atea Pharmaceuticals director Bruce Polsky reported routine equity compensation changes. On June 18, 2026, he exercised 29,600 restricted stock units into Common Stock at no cost, bringing his direct Common Stock holdings to 124,806 shares.

He also received new awards: a stock option for 37,700 shares of Common Stock at an exercise price of $4.36 per share, vesting in twelve equal monthly installments after June 18, 2026, and 26,700 restricted stock units that vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, in each case subject to continued service. The filing shows no share sales, only grants and exercises related to compensation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
insider
-
Rhea-AI Summary

Atea Pharmaceuticals director Polly A. Murphy reported equity compensation activity and an RSU vesting-related share delivery. On June 18, 2026, RSUs covering 29,600 shares of common stock were exercised into common stock, leaving her with 121,745 common shares directly held.

On the same date, she received a stock option grant for 37,700 shares of common stock at an exercise price of $4.36 per share, vesting in twelve substantially equal monthly installments through June 18, 2027, and expiring on June 17, 2036. She was also granted 26,700 restricted stock units, each representing one share of common stock, vesting in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
insider
-
Rhea-AI Summary

Atea Pharmaceuticals director Jerome M. Adams reported equity compensation and a routine derivative exercise. On June 18, 2026, he exercised 29,600 shares of previously granted restricted stock units into Common Stock, leaving him with 92,350 Common shares held directly.

On the same date, he received a new grant of 37,700 stock options with a $4.36 exercise price, expiring on June 17, 2036, which vest in twelve equal monthly installments after June 18, 2026. He was also granted 26,700 restricted stock units that vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to his continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
insider
Rhea-AI Summary

Atea Pharmaceuticals director Arthur S. Kirsch received new equity awards. He was granted stock options covering 37,700 shares of common stock at an exercise price of $4.36 per share. These options vest in twelve substantially equal monthly installments after June 18, 2026 and are fully vested by June 18, 2027, subject to his continued service.

Kirsch also received 26,700 restricted stock units, each representing a contingent right to one share of common stock. These RSUs vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, conditioned on continued service through the vesting date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
insider
-
Rhea-AI Summary

Atea Pharmaceuticals reported results from its 2026 annual stockholder meeting. A total of 59,742,819 shares of common stock were represented, about 74.65% of shares outstanding as of the April 24, 2026 record date, indicating strong participation.

Stockholders elected three Class III directors—Jerome Adams, MD, MPH, Howard Berman, PhD, and Barbara Duncan—to serve until the 2029 annual meeting and until their successors are elected and qualified. They also ratified KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved, on an advisory basis, the executive compensation program for the company’s named executive officers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
current report
-
Rhea-AI Summary

Atea Pharmaceuticals director Polly A. Murphy reported an open-market purchase of 6,100 shares of Common Stock on May 18, 2026 at a weighted average price of $4.1715 per share. Following this trade, she directly owns 92,145 shares of Atea Pharmaceuticals.

The shares were bought in multiple transactions at prices ranging from $4.14 to $4.19 per share. This Form 4/A amends a prior Form 4 only to correct the transaction date, which had been mistakenly reported as May 18, 2025 instead of May 18, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.25%
Tags
insider
Rhea-AI Summary

Atea Pharmaceuticals director Polly A. Murphy reported an open-market purchase of 6,100 shares of Common Stock. The shares were bought on May 18, 2025 at a weighted average price of $4.1715 per share, with individual trade prices ranging from $4.14 to $4.19 per share. Following this transaction, Murphy directly holds 92,145 shares of Atea Pharmaceuticals common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
insider
-
Rhea-AI Summary

Atea Pharmaceuticals reported a Q1 2026 net loss of $45.4 million, compared with $34.3 million a year earlier, as it increased investment in late-stage antiviral programs.

Research and development expenses rose to $41.1 million, driven mainly by Phase 3 hepatitis C trials and hepatitis E preclinical work, while general and administrative costs declined to $6.9 million as the company managed overhead and stock-based compensation.

Atea ended March 31, 2026 with $256.0 million in cash, cash equivalents and marketable securities and expects this to fund operations through 2027 while it completes its global HCV Phase 3 program, advances AT-587 into a planned Phase 1 HEV study, and maintains an unused $200.0 million at-the-market stock offering facility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.91%
Tags
quarterly report
-
Rhea-AI Summary

Atea Pharmaceuticals reported a wider net loss for the first quarter of 2026 as it increased investment in its late-stage antiviral pipeline. Net loss was $45.4 million, or $(0.57) per share, compared with $34.3 million, or $(0.40) per share, a year earlier.

Research and development spending rose to $41.1 million, mainly to fund Phase 3 HCV trials and HEV preclinical work, while general and administrative expenses declined to $6.9 million. Atea ended March 31, 2026 with $256.0 million in cash, cash equivalents and marketable securities.

The company highlighted progress in its hepatitis C program, with Phase 3 C-BEYOND topline results expected in mid-2026 and C-FORWARD results around year-end 2026. It also plans to start a Phase 1 trial of HEV candidate AT-587 in mid-2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.91%
Tags
current report
Rhea-AI Summary

ATEA PHARMACEUTICALS INC reports that FMR LLC beneficially owned 11,950,771.87 shares of Common Stock, representing 15.0% of the class as of 03/31/2026.

The filing shows FMR LLC has sole dispositive power over 11,950,771.87 shares and sole voting power reported as 11,949,098. The disclosure notes that Fidelity Growth Company Commingled Pool held 6,535,486 shares (8.2%) as of 03/31/2026. The amendment is signed by an authorized representative under a power of attorney.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
ownership

FAQ

How many Atea Pharmaceuticals (AVIR) SEC filings are available on StockTitan?

StockTitan tracks 58 SEC filings for Atea Pharmaceuticals (AVIR), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Atea Pharmaceuticals (AVIR)?

The most recent SEC filing for Atea Pharmaceuticals (AVIR) was filed on November 19, 2026.